Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
Tan Q, Dai L, Wang Y, Liu S, Liang T, Luo R, Wang S, Lou N, Chen H, Zhou Y, Zhong Q, Yang J, Xing P, Hu X, Liu Y, Zhou S, Yao J, Wu D, Zhang Z, Tang L, Yu X, Han X, Shi Y.
Tan Q, et al. Among authors: tang l.
Cancer Immunol Immunother. 2022 Jul;71(7):1681-1691. doi: 10.1007/s00262-021-03106-z. Epub 2021 Nov 24.
Cancer Immunol Immunother. 2022.
PMID: 34817638
Free PMC article.